Effect of polysorbate 80 on the intranasal absorption and brain distribution of tetramethylpyrazine phosphate in rats.


Journal

Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 1 9 2018
medline: 18 6 2019
entrez: 1 9 2018
Statut: ppublish

Résumé

Drug delivery to the brain is limited by the blood-brain barrier (BBB). Intranasal delivery is a non-invasive route of drug administration which can bypass the BBB and contributed to a direct and rapid transport of drugs to the brain. However, intrinsic drug distribution to the brain after intranasal administration may not be sufficient to achieve required clinical efficacy. In this study, taking 2,3,5,6-tetramethylpyrazine (TMPP) as a model drug, the feasibility of using polysorbate 80 as an absorption enhancer and message guider to increase drug distribution in the brain was employed. After intravenous/intranasal administration of TMPP formulations with/without polysorbate 80, drug concentration in both plasma and brain was measured at specific time points, and the pharmacokinetic parameters were compared. It was demonstrated that compared with intravenous administration, brain targeting efficiency of TMPP was improved remarkably by intranasal route. Upon intranasal administration, the addition of polysorbate 80 significantly increased TMPP concentration in both plasma and brain linearly up to polysorbate 80 concentration 2%. Based on drug targeting efficiency, drug targeting index, and nose-to-brain direct transport percentage, polysorbate 80 decreased the nose-to-brain direct transport ratio of TMPP in a polysorbate 80 concentration-dependent manner although the total brain targeting efficiency was unchanged, with significantly enhanced absolute drug concentration in the brain achieved. In summary, polysorbate 80 is a promising excipient to increase drug concentration in both plasma and brain via intranasal route.

Identifiants

pubmed: 30168052
doi: 10.1007/s13346-018-0580-y
pii: 10.1007/s13346-018-0580-y
doi:

Substances chimiques

Polysorbates 0
Pyrazines 0
tetramethylpyrazine V80F4IA5XG

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

311-318

Références

Biomaterials. 2011 Sep;32(26):6213-25
pubmed: 21616528
J Control Release. 2014 Sep 10;189:133-40
pubmed: 24997277
Chem Pharm Bull (Tokyo). 1974 Mar;22(3):523-8
pubmed: 4417750
J Pharm Sci. 1966 Apr;55(4):394-8
pubmed: 5960291
Drug Des Devel Ther. 2017 Jan 27;11:325-335
pubmed: 28184152
J Control Release. 2010 Feb 25;142(1):22-30
pubmed: 19850092
J Control Release. 2011 Aug 25;154(1):103-7
pubmed: 21616104
Int J Pharm. 2004 May 4;275(1-2):85-96
pubmed: 15081140
Int J Nanomedicine. 2015 Jun 10;10:3921-35
pubmed: 26089668
Int J Pharm. 2008 Feb 12;349(1-2):196-205
pubmed: 17904315
Vascul Pharmacol. 2002 Jun;38(6):323-37
pubmed: 12529927
J Chromatogr B Biomed Sci Appl. 1999 Mar 19;724(2):303-9
pubmed: 10219672
Eur J Pharm Biopharm. 2008 Sep;70(1):75-84
pubmed: 18472255
J Control Release. 2002 Jun 17;81(3):379-88
pubmed: 12044576
Pharm Res. 1999 Oct;16(10):1564-9
pubmed: 10554098
Int J Pharm. 2013 Aug 16;452(1-2):300-10
pubmed: 23684658
Peptides. 2011 Jul;32(7):1526-9
pubmed: 21600257
J Pharm Bioallied Sci. 2012 Jan;4(1):2-9
pubmed: 22368393
Adv Drug Deliv Rev. 2012 May 15;64(7):614-28
pubmed: 22119441
Int J Pharm. 2017 Aug 30;529(1-2):134-160
pubmed: 28642203
J Control Release. 2017 Dec 28;268:364-389
pubmed: 28887135
Eur J Pharm Biopharm. 2014 Sep;88(1):8-27
pubmed: 24681294
Eur J Pharm Biopharm. 2008 Nov;70(3):874-81
pubmed: 18656537
Planta Med. 1983 Feb;47(2):89
pubmed: 6844454
Int J Pharm. 2001 Mar 23;216(1-2):61-6
pubmed: 11274807
J Drug Target. 2002 Jun;10(4):317-25
pubmed: 12164380
J Pharm Sci. 1999 Aug;88(8):754-8
pubmed: 10430537
J Ethnopharmacol. 2017 Sep 14;209:116-123
pubmed: 28733193
Int J Pharm. 2003 Sep 16;263(1-2):1-7
pubmed: 12954175
Drug Dev Ind Pharm. 2012 Jan;38(1):123-8
pubmed: 21721852
Yao Xue Xue Bao. 1989;24(12):881-6
pubmed: 2638138
J Neuroimmunol. 2004 Jun;151(1-2):66-77
pubmed: 15145605
PLoS One. 2015 Aug 06;10(8):e0134722
pubmed: 26248340
Curr Opin Pharmacol. 2006 Oct;6(5):494-500
pubmed: 16839816

Auteurs

Mingyue Gao (M)

School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.

Dan Mei (D)

School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.

Yingnan Huo (Y)

School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China.

Shirui Mao (S)

School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, China. maoshirui@syphu.edu.cn.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH